- Home
- CCEC vs CSTL Comparison
CCEC vs CSTL Comparison
Compare CCEC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | CSTL |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CCEC | CSTL |
|---|---|---|
| Price | $21.41 | $42.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $25.67 | ★ $46.00 |
| AVG Volume (30 Days) | 4.7K | ★ 328.4K |
| Earning Date | 02-06-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ 304.00 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $421,795,000.00 | $343,530,000.00 |
| Revenue This Year | $14.29 | $2.54 |
| Revenue Next Year | $12.32 | N/A |
| P/E Ratio | $8.36 | ★ N/A |
| Revenue Growth | ★ 32.74 | 10.15 |
| 52 Week Low | $14.09 | $14.59 |
| 52 Week High | $24.83 | $42.18 |
Technical Indicators
Market Signals| Indicator | CCEC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 67.97 |
| Support Level | $19.93 | $39.74 |
| Resistance Level | $21.50 | $41.60 |
| Average True Range (ATR) | 0.54 | 1.73 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 82.53 | 83.22 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.